Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03110822 | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | recruiting | Phase 1 | 134 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM(HO147SMM) | active not recruiting | Phase 2 | 58 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Nov 1, 2023 |
| clinicaltrials |
| NCT05849857 | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries(MERLIN) | recruiting | Phase 2 | 80 | Oslo University HospitalOTHER | 2 | Nov 1, 2023 | clinicaltrials |
| NCT05328258 | Use of GnRHa During Chemotherapy for Fertility Protection(ProFertil) | recruiting | Phase 3 | 500 | Kenny Rodriguez-WallbergOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06097455 | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma(CARTD-BG-1) | not yet recruiting | Early Phase 1 | 40 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04808037 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma(BelaRd) | active not recruiting | Phase 1 / Phase 2 | 66 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05230680 | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | recruiting | Phase 1 / Phase 2 | 41 | Won Seog KimOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05923502 | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT04349358 | FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)(MIM) | recruiting | N/A | 38 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06084962 | A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | recruiting | Phase 1 | 40 | He HuangOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT04558931 | Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | recruiting | Phase 2 | 62 | Karolinska InstitutetOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06075238 | Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | not yet recruiting | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06070246 | Navigating the Clinical Research Process for Lymphoma | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04758975 | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)(VALUABLE) | recruiting | Phase 2 | 55 | Paolo GhiaOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT06065852 | National Registry of Rare Kidney Diseases(RaDaR) | recruiting | — | 35,000 | UK Kidney AssociationOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT04908228 | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL(FIGHT) | recruiting | Phase 2 | 53 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05444712 | Transplantation After Complete Response In Patients With T-cell Lymphoma(TRANSCRIPT) | recruiting | N/A | 204 | Hospices Civils de LyonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | active not recruiting | Phase 3 | 56 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06049472 | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06049485 | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05768529 | Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00003861 | Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | active not recruiting | — | 840 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT04613557 | Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma(IMMUNICY-1) | active not recruiting | Phase 1 | 18 | Celyad Oncology SAINDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
| NCT03127761 | Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma | recruiting | — | 544 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | recruiting | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05996367 | Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma | recruiting | N/A | 50 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05982223 | Integrative Medicine in Lymphoma Survivors | recruiting | N/A | 90 | Bnai Zion Medical CenterOTHER_GOV | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05968417 | Myeloma Novel Drug Discovery Ver 1.2(DISCO) | recruiting | — | 250 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05965115 | The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study(CHAPERONE) | recruiting | — | 10,000 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05967949 | A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. | recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970198 | Helical Tomotherapy in Multiple Myeloma | recruiting | N/A | 58 | Fuling ZhouOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05846750 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 59 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05948033 | CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05909826 | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM(KMM-KCd) | not yet recruiting | Phase 2 | 49 | Dong-A University HospitalOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05814848 | A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Phase 4 | 13 | Changhai HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05899621 | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | recruiting | — | 332 | Ruijin HospitalOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05846763 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study | recruiting | — | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT05831865 | Frontline of ASCT in High-risk DLBCL(Essential) | recruiting | — | 175 | Peking University People's HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05842707 | Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 48 | Aibin Liang，MD，Ph.D.OTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05840575 | Investigating Cognitive Impairment in Young Patients With Cancer Prospectively(MyBrain) | recruiting | — | 100 | Rigshospitalet, DenmarkOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04006561 | Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost | recruiting | — | 36 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05833893 | Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma | recruiting | Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 1, 2023source: clinicaltrials